Stock GYRE GYRE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Gyre Therapeutics, Inc.

Equities

GYRE

US4037831033

End-of-day quote Nasdaq
Other stock markets
 23:00:00 27/05/2024 BST 		5-day change 1st Jan Change
10.15 USD -15.35% Intraday chart for Gyre Therapeutics, Inc. -25.04% -60.49%
05-09 Gyre Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-03 Gyre Therapeutics Insider Sold Shares Worth $323,000, According to a Recent SEC Filing MT

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Gyre Pharmaceuticals Receives IND Approval from China’s NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension
GL
Gyre Therapeutics Announces Expected Addition to the Russell 2000® and Russell 3000® Indexes
GL
Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
GL
Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
AQ
Gyre Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Gyre Therapeutics Insider Sold Shares Worth $323,000, According to a Recent SEC Filing
MT
Gyre Therapeutics Swings to Fiscal 2023 Net Loss, Revenue Rises
MT
Gyre Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
GL
Gyre Therapeutics Expands Board of Directors with Appointment of Rodney L. Nussbaum
GL
Gyre Therapeutics Announces Appointment of Rodney L. Nussbaum to the Board of Directors and Member of Audit Committee
CI
Gyre Therapeutics, Inc. Announces Board Changes
CI
Gyre Therapeutics, Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Gyre Therapeutics, Inc. Announces CEO Changes, Effective January 15, 2024
CI
Gyre Therapeutics, Inc. and Beijing Continent Pharmaceuticals Co., Ltd. Announce the Resignation of Charles Wu as Member of the Board of Directors. Effective on January 15, 2024
CI
Totus Medicines Announces Appointment of Nassim Usman, Ph.D., as President & CEO and the Closing of a $66M Series B Funding
PR
Gyre Therapeutics Presents Poster at the American Association for the Study of Liver Diseases (AASLD) Annual Liver Meeting
GL
Gyre Therapeutics Presents Poster at the American Association for the Study of Liver Diseases (AASLD) Annual Liver Meeting
AQ
Reverse Split: 1 of 15
FA
Gyre Therapeutics, Inc. Announces Management Changes
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GYRE Stock
  4. News Gyre Therapeutics, Inc.